Lessee, Operating Lease, Liability, to be Paid, Year Two of KalVista Pharmaceuticals, Inc. from 31 Jul 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
KalVista Pharmaceuticals, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two in USD history and change rate from 31 Jul 2019 to 30 Sep 2025.
  • KalVista Pharmaceuticals, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Two for the quarter ending 30 Sep 2025 was $2,735,000, a 71% increase year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year Two, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Two, YoY Quarterly Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,735,000 +$1,136,000 +71% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $1,725,000 +$120,000 +7.5% 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q1 2025 $1,769,000 -$127,000 -6.7% 30 Apr 2025 10-K 10 Jul 2025 2025 FY
Q3 2024 $1,599,000 -$207,000 -11% 31 Oct 2024 10-Q 12 Mar 2025 2025 Q3
Q2 2024 $1,605,000 -$209,000 -12% 31 Jul 2024 10-Q 05 Sep 2024 2025 Q1
Q1 2024 $1,896,000 +$52,000 +2.8% 30 Apr 2024 10-K 11 Jul 2024 2024 FY
Q4 2023 $1,813,000 +$17,000 +0.95% 31 Jan 2024 10-Q 11 Mar 2024 2024 Q3
Q3 2023 $1,806,000 +$37,000 +2.1% 31 Oct 2023 10-Q 07 Dec 2023 2024 Q2
Q2 2023 $1,814,000 +$36,000 +2% 31 Jul 2023 10-Q 07 Sep 2023 2024 Q1
Q1 2023 $1,844,000 +$340,000 +23% 30 Apr 2023 10-K 10 Jul 2023 2023 FY
Q4 2022 $1,796,000 +$285,000 +19% 31 Jan 2023 10-Q 09 Mar 2023 2023 Q3
Q3 2022 $1,769,000 +$478,000 +37% 31 Oct 2022 10-Q 08 Dec 2022 2023 Q2
Q2 2022 $1,778,000 +$486,000 +38% 31 Jul 2022 10-Q 08 Sep 2022 2023 Q1
Q1 2022 $1,504,000 +$397,000 +36% 30 Apr 2022 10-K 07 Jul 2022 2022 FY
Q4 2021 $1,511,000 +$1,092,000 +261% 31 Jan 2022 10-Q 10 Mar 2022 2022 Q3
Q3 2021 $1,291,000 +$1,046,000 +427% 31 Oct 2021 10-Q 09 Dec 2021 2022 Q2
Q2 2021 $1,292,000 +$1,050,000 +434% 31 Jul 2021 10-Q 09 Sep 2021 2022 Q1
Q1 2021 $1,107,000 +$724,000 +189% 30 Apr 2021 10-K 13 Jul 2021 2021 FY
Q4 2020 $419,000 -$207,000 -33% 31 Jan 2021 10-Q 11 Mar 2021 2021 Q3
Q3 2020 $245,000 -$380,000 -61% 31 Oct 2020 10-Q 10 Dec 2020 2021 Q2
Q2 2020 $242,000 -$374,000 -61% 31 Jul 2020 10-Q 14 Sep 2020 2021 Q1
Q1 2020 $383,000 30 Apr 2020 10-K 01 Jul 2020 2020 FY
Q4 2019 $626,000 31 Jan 2020 10-Q 10 Mar 2020 2020 Q3
Q3 2019 $625,000 31 Oct 2019 10-Q 03 Dec 2019 2020 Q2
Q2 2019 $616,000 31 Jul 2019 10-Q 09 Sep 2019 2020 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.